(Q46542862)

23 December 2017

title

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib (English)

1 reference

23 December 2017

0 references

1

1 reference

23 December 2017

author name string

L M Reilly

series ordinal

2

1 reference

23 December 2017

P Gerami

series ordinal

3

1 reference

23 December 2017

J Guitart

series ordinal

4

1 reference

23 December 2017

publication date

10 June 2008

1 reference

23 December 2017

published in

Annals of Oncology

1 reference

23 December 2017

volume

19

1 reference

23 December 2017

issue

11

1 reference

23 December 2017

page(s)

1955-1961

1 reference

23 December 2017

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Antiangiogenic agents: an update on small molecule VEGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Effects of fibroblasts and microenvironment on epidermal regeneration and tissue function in long-term skin equivalents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Human keratinocytes are a major source of cutaneous platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Epithelial-stromal interactions in basal cell cancer: the PDGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Managing side effects of angiogenesis inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

Sorafenib: a promising new targeted therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN389

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN389

1 reference

23 December 2017

1 reference

23 December 2017